Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection is indicated for: - prophylaxis and treatment of venous thrombosis and pulmonary embolism - prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease - atrial fibrillation with embolization - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) - prevention of clotting in arterial and cardiac surgery - prophylaxis and treatment of peripheral arterial embolism - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures the use of heparin sodium is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see warnings and precautions (5.3)] - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions (6.1)] - in whom su

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole

United States - English - NLM (National Library of Medicine)

safecor health, llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole b

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 1 ml - heparin sodium injection is indicated for: - prophylaxis and treatment of venous thrombosis and pulmonary embolism; - prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; - atrial fibrillation with embolization; - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); - prevention of clotting in arterial and cardiac surgery; - prophylaxis and treatment of peripheral arterial embolism. - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. the use of heparin sodium injection is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see warnings and precautions (5.3)] ; - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.3) and use in specific populations (8.6)] - active major bleeding. - bacterial endocarditi